Cognitive function drug proves beneficial for patients with brain cancer

October 7, 2013, Emory University

(Medical Xpress)—Whole-brain radiotherapy (WBRT) proves to be a positive therapeutic and survival tool in the treatment of brain tumors in adults, but the effect of WBRT on long-term brain function and performance is a major concern. Because of this, researchers at Emory's Nell Hodgson Woodruff School of Nursing and the Winship Cancer Institute conducted a study that highlighted positive outcomes in long-term cognitive function due to the use of the cognitive drug Memantine.

Deborah Watkins-Bruner, PhD, RN, professor at the Nell Hodgson Woodruff School of Nursing and associate director of cancer outcomes at Winship Cancer Institute at Emory, was part of a team of researchers who selected 508 eligible adult WBRT patients diagnosed with brain cancer. Participants were randomly selected to receive placebo or Memantine within three days of their initial WBRT and for 24 weeks in graduated doses.

A series of cognitive function tests was performed after the start of the study drug for 54 weeks. All patients underwent neurologic exams, history and physical exams, performance status, brain MRI and CT and other neuropsychological evaluations and assessments.

"We were pleased that the preliminary results showed better cognitive function over time in those who took Memantine," explains Watkins-Bruner. "We specifically saw a delay in the time of and reductions in the rates of memory loss, executive function and processing-speed declines. Further exploration through ongoing trials will answer some of the questions that remain, but I believe that this is a very positive step in the prevention of ."

Complete findings of the study are available in Neuro-Oncology.

Explore further: Adult cancer patients younger than 50 with limited brain mets have improved OS after SRS alone

More information: neuro-oncology.oxfordjournals. … 7f-a2a7-33eaf1aa6635

Related Stories

Adult cancer patients younger than 50 with limited brain mets have improved OS after SRS alone

September 23, 2013
When treated with stereotactic radiosurgery (SRS), that is not combined with whole brain radiotherapy (WBRT), adult brain cancer patients who were 50 years old and younger were found to have improved survival, according to ...

Drug combination shrinks secondary brain tumours in breast cancer without substantial side effects of radiotherapy

November 1, 2012
The sizeable and increasing proportion of women with advanced breast cancer whose disease has spread to the brain could be effectively treated systemically with a combination of two drugs, sparing them the debilitating neurological ...

New surgical approach may improve cognitive function in patients with brain cancer

September 26, 2013
A new approach to treating cancer that has spread to the brain is able to preserve and, in some cases, improve cognitive function in patients, while achieving local control of tumor progression. A study led by researchers ...

Simple urine test may help identify individuals with diabetes at risk for cognitive decline

August 29, 2013
The presence of protein in the urine may be a marker of risk for future cognitive decline in patients with type 2 diabetes and normal kidney function, according to a study appearing in an upcoming issue of the Clinical Journal ...

Cognitive rehabilitation improves brain function in cancer survivors

September 20, 2013
Cancer survivors who experience memory and thinking problems may benefit from cognitive rehabilitation, according to a new study led by Monique Cherrier, a UW associate professor of psychiatry and behavioral sciences.

Brain atrophy linked with cognitive decline in diabetes

September 12, 2013
New research has shown that cognitive decline in people with Type 2 Diabetes is likely due to brain atrophy, or shrinkage, that resembles patterns seen in the early stages of Alzheimer's disease.

Recommended for you

New approach attacks 'undruggable' cancers from the outside in

January 23, 2018
Cancer researchers have made great strides in developing targeted therapies that treat the specific genetic mutations underlying a patient's cancer. However, many of the most common cancer-causing genes are so central to ...

Study: Cells of three advanced cancers die with drug-like compounds that reverse chemo failure

January 23, 2018
Researchers at Southern Methodist University have discovered three drug-like compounds that successfully reverse chemotherapy failure in three of the most commonly aggressive cancers—ovarian, prostate and breast.

'Hijacker' drives cancer in some patients with high-risk neuroblastoma

January 23, 2018
Researchers have identified mechanisms that drive about 10 percent of high-risk neuroblastoma cases and have used a new approach to show how the cancer genome "hijacks" DNA that regulates other genes. The resulting insights ...

Enzyme inhibitor combined with chemotherapy delays glioblastoma growth

January 23, 2018
In animal experiments, a human-derived glioblastoma significantly regressed when treated with the combination of an experimental enzyme inhibitor and the standard glioblastoma chemotherapy drug, temozolomide.

Researchers identify a protein that keeps metastatic breast cancer cells dormant

January 23, 2018
A study headed by ICREA researcher Roger Gomis at the Institute for Research in Biomedicine (IRB Barcelona) has identified the genes involved in the latent asymptomatic state of breast cancer metastases. The work sheds light ...

Boosting cancer therapy with cross-dressed immune cells

January 22, 2018
Researchers at EPFL have created artificial molecules that can help the immune system to recognize and attack cancer tumors. The study is published in Nature Methods.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.